Original Article

Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice

Correspondence to: Stephen G. Young

Over the past 10 years, many laboratories have investigated lipid metabolism and atherogenesis with a variety of transgenic and gene knockout mouse models. Although many of these studies have yielded valuable insights, some have been hampered by a paucity of useful antibodies against mouse proteins. For example, many laboratories have analyzed genetic and dietary interventions affecting lipoprotein metabolism without useful antibodies against mouse apolipoprotein (apo) B. In this study, we sought to develop highly specific monoclonal antibodies against mouse apoB-100. To achieve this goal, gene-targeted mice that synthesize exclusively apoB-48 (apoB-48-only mice) were immunized with mouse apoB-100. The immune response against apoB-100 was robust, as judged by high titers of antibodies against mouse apoB-100. After fusing the splenic lymphocytes of the apoB-48-only mice with a myeloma cell line, we identified and cloned hybridomas that produced mouse apoB-100-specific monoclonal antibodies. Those antibodies were useful for developing sensitive and specific immunoassays for mouse apoB-100.

This study illustrates the feasibility and utility of using gene-targeted mice to develop monoclonal antibodies against mouse proteins.—Zlot, C. H., L. M. Flynn, M. M. Véniant, E. Kim, M. Raabe, S. P. A. McCormick, P. Ambroziak, L. M. McEvoy, and S. G. Young. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 1999. 40: 76–84.

Supplementary key words: radioimmunoassay, transgenic mice, cholesterol, lipoproteins

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. M. Buga, J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M. Navab, S. T. Reddy, G. M. Anantharamaiah, et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet J. Lipid Res., January 1, 2008; 49(1): 192 - 205. [Abstract] [Full Text] [PDF]

				X. Feng, H. Li, A. A. Rumbin, X. Wang, A. La Cava, K. Brechtelsbauer, L. W. Castellani, J. L. Witztum, A. J. Lusis, and B. P. Tsao ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia J. Lipid Res., April 1, 2007; 48(4): 794 - 805. [Abstract] [Full Text] [PDF]

				T. Yamashita, S. Freigang, C. Eberle, J. Pattison, S. Gupta, C. Napoli, and W. Palinski Maternal Immunization Programs Postnatal Immune Responses and Reduces Atherosclerosis in Offspring Circ. Res., September 29, 2006; 99(7): E51 - E64. [Abstract] [Full Text] [PDF]

				A. T. Nguyen, T. Hirama, V. Chauhan, R. MacKenzie, and R. Milne Binding characteristics of a panel of monoclonal antibodies against the ligand binding domain of the human LDLr J. Lipid Res., July 1, 2006; 47(7): 1399 - 1405. [Abstract] [Full Text] [PDF]

				R. Out, M. Hoekstra, S. C. A. de Jager, P. de Vos, D. R. van der Westhuyzen, N. R. Webb, M. Van Eck, E. A. L. Biessen, and T. J. C. Van Berkel Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice J. Lipid Res., June 1, 2005; 46(6): 1172 - 1181. [Abstract] [Full Text] [PDF]

				M. Schneider, J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins J. Lipid Res., April 1, 2005; 46(4): 769 - 778. [Abstract] [Full Text] [PDF]

				C. A. Reardon, E. R. Miller, L. Blachowicz, J. Lukens, C. J. Binder, J. L. Witztum, and G. S. Getz Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice J. Lipid Res., July 1, 2004; 45(7): 1347 - 1354. [Abstract] [Full Text] [PDF]

				K. Faber, O. Axler, B. Dahlback, and L. B. Nielsen Characterization of apoM in normal and genetically modified mice J. Lipid Res., July 1, 2004; 45(7): 1272 - 1278. [Abstract] [Full Text] [PDF]

				X. Wang, V. Chauhan, A. T. Nguyen, J. Schultz, J. Davignon, S. G. Young, J. Boren, T. L. Innerarity, H. Rutai, and R. W. Milne Immunochemical evidence that human apoB differs when expressed in rodent versus human cells J. Lipid Res., March 1, 2003; 44(3): 547 - 553. [Abstract] [Full Text] [PDF]

				G. K. Leung, M. M. Veniant, S. K. Kim, C. H. Zlot, M. Raabe, J. Bjorkegren, R. A. Neese, M. K. Hellerstein, and S. G. Young A Deficiency of Microsomal Triglyceride Transfer Protein Reduces Apolipoprotein B Secretion J. Biol. Chem., March 10, 2000; 275(11): 7515 - 7520. [Abstract] [Full Text] [PDF]